Where is Espervita Therapeutics headquartered?

Esperion Therapeutics is recorded with headquarters in ann arbor, USA in NovaPharmaNews public regulatory and sponsor datasets.

Is Espervita Therapeutics publicly traded?

Yes — Espervita Therapeutics is listed as a public company with ticker ESPR on NYSE in SEC EDGAR-derived records.

What drugs are associated with Espervita Therapeutics?

We link 1 drug profile(s) where Espervita Therapeutics appears as originator or marketer in FDA or regional approval metadata.

What clinical trials is Espervita Therapeutics sponsoring?

Espervita Therapeutics is linked to 15 pipeline program(s) sourced from ClinicalTrials.gov and EU CTIS where sponsor names match.

What patents list Espervita Therapeutics as applicant?

55 USPTO PatentsView record(s) name Esperion Therapeutics or a normalized variant as applicant.

What pipeline phases does Espervita Therapeutics have in our database?

Phase distribution from linked programs: phase 2: 5, phase 3: 4, phase 1: 3, approved: 2.

How many US-approved drugs are linked to Espervita Therapeutics?

1 linked drug profile(s) include US approval status in openFDA-derived metadata.

Does Espervita Therapeutics hold EU marketing authorisations in our data?

1 linked drug(s) include EMA EPAR approval metadata.

Where does NovaPharmaNews source data on Espervita Therapeutics?

Profiles combine SEC EDGAR (US issuers), FDA openFDA, EMA medicines data, ClinicalTrials.gov, EU CTIS, USPTO PatentsView, and regional PBS/PMDA/NMPA feeds. See /about/data-sources.

Is Espervita Therapeutics data investment advice?

No. This profile is compiled from public regulatory records for professional reference only, not investment or medical advice.

Esperion Therapeutics Pharmaceuticals Company Profile

Name: Esperion Therapeutics intelligence dataset
Creator: NovaPharmaNews
License: https://www.sec.gov/edgar.shtml

Company details

Status: Public
HQ: Ann Arbor, US
Employees: 5
Programs: 15
Drugs: 9
Patents: 55

Official website ↗ All projects Drug pipeline Patents News & analysis

Quick answer

Espervita Therapeutics is a pharma organization headquartered in ann arbor, USA. It trades on NYSE under ticker ESPR. Primary therapeutic focus areas include Hypercholesterolemia, Hyperlipidemia, Cardiovascular Diseases, Diabetes, Hyperlipidemias. NovaPharmaNews links 15 clinical program(s), 1 drug profile(s), and 55 patent record(s) to this entity from public FDA, EMA, ClinicalTrials.gov, and USPTO sources. Pipeline phase mix: phase 2 (5), phase 3 (4), phase 1 (3).

Company snapshot

Dedicated to the discovery and development of metabolic reprogramming therapies targeting areas of unmet medical need

2 approved product(s) across US/EU regulatory metadata.
15 active pipeline program(s) linked via ClinicalTrials.gov.
55 US patent(s) indexed to this assignee profile.

Public regulatory, clinical, patent, and corporate records for Esperion Therapeutics. Not investment advice.

Top assets

View drugs (9) View projects (15)

Lead pipeline drugs

atra
Marketed / approved
bempedoic acid
approved
bempedoic acid, ezetimibe
approved
combination
Marketed / approved

Active clinical programs

Bempedoic Acid + Ezetimibe Fixed-Dose Combination Hyperlipidemias
Phase 3
Bempedoic acid 180 mg tablet Cardiovascular Diseases
Phase 3
ETC-1002 Hypercholesterolemia
Phase 3
bempedoic acid Hypercholesterolemia
Phase 3

Momentum

Proprietary activity score for Esperion Therapeutics.

1 active signal

20 /100 +0 vs 30 days ago

Signal breakdown

Clinical trials 25 30d
Nova articles 0 30d
Patents filed 0 30d
FDA actions 0 30d
SEC filings 0 30d
Conference presentations 0 90d
Pipeline advances 0 30d

Competitor landscape

Therapeutic-area overlap peers from registry and pipeline signals.

Peer + 0 momentum

Amgen

TA overlap score 39.2
Peer + 0 momentum

Tillomed Laboratories

TA overlap score 30.2
Peer + 0 momentum

Silence Therapeutics

TA overlap score 21.6

Recent activity

Latest pipeline, patent, and corporate events for Esperion Therapeutics.

Jun 8, 2026 Clinical update
Bempedoic acid, bempedoic acid — Phase 2
Jun 8, 2026 Clinical update
bempedoic acid — Phase 3
Jun 8, 2026 Clinical update
Bempedoic Acid / Ezetimibe Oral Tablet — Approved
Jun 8, 2026 Clinical update
Bempedoic Acid + Ezetimibe Fixed-Dose Combination — Phase 3
Jun 8, 2026 Clinical update
Bempedoic acid + Ezetimibe FDC Oral Tablet — Phase 2

View all clinical trial activity →

Quick answers

Common questions about this sponsor — for analysts and search.

What is Esperion Therapeutics?

Espervita Therapeutics is a pharma organization headquartered in ann arbor, USA. It trades on NYSE under ticker ESPR. Primary therapeutic focus areas include Hypercholesterolemia, Hyperlipidemia, Cardiovascular Diseases, Diabetes, Hyperlipidemias. NovaPharmaNews links 15 clinical
Is Esperion Therapeutics publicly traded?

Yes. Esperion Therapeutics is listed with ticker ESPR on NYSE per SEC EDGAR records linked on this profile.
What drugs does Esperion Therapeutics develop or market?

We link 9 drug profile(s) where Esperion Therapeutics is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/esperion-therapeutics#company-drugs.
What are the latest developments for Esperion Therapeutics?

In the last 12 months our linked public records show 15 trial program update(s) and 3 US patent grant(s) tied to this profile.
What therapeutic areas does Esperion Therapeutics focus on?

Esperion Therapeutics focuses on Hypercholesterolemia, Hyperlipidemia, Cardiovascular Diseases based on our analysis of their pipeline programs and drug development activities.

Therapeutic focus

Therapeutic area distribution

Pipeline concentration by therapeutic area from linked clinical programs.

Programs by therapeutic area

Others

Cardiology